SLXN (Silexion Therapeutics) EBITDA Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Silexion Therapeutics's EBITDA for the three months ended in Dec. 2024 was $-5.84 Mil. Silexion Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Silexion Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

Silexion Therapeutics EBITDA Margin % Historical Data

The historical data trend for Silexion Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics EBITDA Margin % Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

EBITDA Margin %

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Silexion Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Silexion Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silexion Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Silexion Therapeutics's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Silexion Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Silexion Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-16.477	/	0
	=	%

Silexion Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-5.843	/	0
	=	%

Silexion Therapeutics (NAS:SLXN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Silexion Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871

Website

https://www.silexion.com

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.